The PMPRB has announced it has revisited it’s March 17, 2021 decision regarding timelines for compliance for Grandfathered and Gap medicines. The Board has reset the maximum list price (MLP) compliance timeline for these drugs to 2 PMPRB reporting periods, rather than their amended 1 reporting period timeline.
MLP compliance for grandfathered and gap medicines will be required by July 1, 2022. The stated reason for this decision is the evolving COVID-19 pandemic. This is welcome news for all stakeholders. The Board conducted a Notice and Comment on their proposal to implement a 1-period compliance timeline. A clear majority of stakeholder responses to the Notice and Comment opposed the proposal.
The message from the board can be found here.
For inquiries on how PDCI can help with navigating your pricing needs, please contact Kimberly Robinson, Director, Pricing and Market Access.